Lates News

The editorial of The Washington Post criticizes the Food and Drug Administration's refusal to review Moderna's application for an mRNA flu vaccine, stating that although the data is positive, the standards are constantly changing. The agency, however, disagrees with the bias claims. Moderna's stock remained steady on Thursday morning.